SBIOvsETF 2ETF Comparison
VS
ETF 2
Choose a second ETF to run a side-by-side ETF comparison with SBIO, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
SBIO performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 07/28/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | SBIO ETF 2 | -0.90%– | +19.27%– | +24.68%– | +92.66%– | +109.07%– | +44.84%– |
| Flows | SBIO ETF 2 | +$17M– | +$23M– | +$41M– | +$51M– | +$20M– | -$24M– |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | SBIO ETF 2 | +35.26%– | +30.57%– | +30.92%– | +33.91%– |
| Max drawdown | SBIO ETF 2 | -10.73%– | -12.63%– | -42.12%– | -52.50%– |
| Max drawdown duration | SBIO ETF 2 | 43d– | 60d– | 331d– | 1479d– |
Trading data
SBIO | ETF 2 | |
Last sale 7/29/2026 at 1:30 PM | $63.14 | – |
| Previous close 07/28/2026 | $63.52 | – |
| Consolidated volume 07/28/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of June 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
SBIO | ETF 2 | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 7/29/2026 at 1:30 PM
Live
Closed
SBIO | ETF 2 | |
|---|---|---|
| Last price | $63.14 | – |
| 1D performance | -0.60% | – |
| AuM | $202.41 M | – |
| E/R | 0.5% | – |
Characteristics
SBIO | ETF 2 | |
|---|---|---|
| Management strategy | Passive | – |
| Provider | ALPS | – |
| Benchmark | S-Network Medical Breakthroughs Index | – |
| N° of holdings | 103 | – |
| Asset class | Equities | – |
| Trailing 12m distribution yield | Join | Join |
| Inception date | December 30, 2014 | – |
| ESG | No | – |
Advertisement
Exposure
Countries
SBIO
USA
88.02%
Other
11.98%
ETF 2
Sectors
SBIO
Healthcare
99.06%
Other
0.94%
ETF 2
Diversification
SBIO
Total weight of top 15 holdings out of 15
40.08%
ETF 2
–
Top 15 holdings
Data as of June 30, 2026
SBIO
Apogee Therapeutics, Inc.
4.36%
CG Oncology, Inc.
3.33%
Xenon Pharmaceuticals, Inc.
3.09%
Oruka Therapeutics, Inc.
3.05%
Dianthus Therapeutics, Inc.
2.83%
Travere Therapeutics, Inc.
2.80%
Definium Therapeutics, Inc.
2.73%
Veradermics, Inc.
2.72%
Edgewise Therapeutics, Inc.
2.32%
ACADIA Pharmaceuticals, Inc.
2.30%
Denali Therapeutics, Inc.
2.17%
Relay Therapeutics, Inc.
2.17%
NewAmsterdam Pharma Co. NV
2.10%
Crinetics Pharmaceuticals, Inc.
2.09%
Structure Therapeutics, Inc.
2.02%
ETF 2
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Advertisement
Latest news about SBIO
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
SBIO
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
SBIO
Advertisement
Advertisement
